JP2022541517A5 - - Google Patents

Info

Publication number
JP2022541517A5
JP2022541517A5 JP2022502910A JP2022502910A JP2022541517A5 JP 2022541517 A5 JP2022541517 A5 JP 2022541517A5 JP 2022502910 A JP2022502910 A JP 2022502910A JP 2022502910 A JP2022502910 A JP 2022502910A JP 2022541517 A5 JP2022541517 A5 JP 2022541517A5
Authority
JP
Japan
Prior art keywords
adc
alkyl
pharmaceutically acceptable
acceptable salt
thiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022502910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541517A (ja
JP7576779B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042815 external-priority patent/WO2021016204A1/en
Publication of JP2022541517A publication Critical patent/JP2022541517A/ja
Publication of JP2022541517A5 publication Critical patent/JP2022541517A5/ja
Application granted granted Critical
Publication of JP7576779B2 publication Critical patent/JP7576779B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022502910A 2019-07-19 2020-07-20 抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用 Active JP7576779B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876590P 2019-07-19 2019-07-19
US62/876,590 2019-07-19
US202063019212P 2020-05-01 2020-05-01
US63/019,212 2020-05-01
PCT/US2020/042815 WO2021016204A1 (en) 2019-07-19 2020-07-20 Antibody-sting agonist conjugates and their use in immunotherapy

Publications (3)

Publication Number Publication Date
JP2022541517A JP2022541517A (ja) 2022-09-26
JP2022541517A5 true JP2022541517A5 (cg-RX-API-DMAC7.html) 2023-07-26
JP7576779B2 JP7576779B2 (ja) 2024-11-01

Family

ID=71995149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502910A Active JP7576779B2 (ja) 2019-07-19 2020-07-20 抗体-stingアゴニスト複合体および免疫療法におけるそれらの使用

Country Status (13)

Country Link
US (3) US11033635B2 (cg-RX-API-DMAC7.html)
EP (1) EP3999118A1 (cg-RX-API-DMAC7.html)
JP (1) JP7576779B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054794A (cg-RX-API-DMAC7.html)
CN (2) CN117838878A (cg-RX-API-DMAC7.html)
AU (1) AU2020315802A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000854A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147890A1 (cg-RX-API-DMAC7.html)
IL (1) IL289866A (cg-RX-API-DMAC7.html)
MX (1) MX2022000815A (cg-RX-API-DMAC7.html)
TW (1) TWI877186B (cg-RX-API-DMAC7.html)
WO (1) WO2021016204A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201988B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033635B2 (en) * 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy
US20240218009A1 (en) * 2021-04-21 2024-07-04 Merck Sharp & Dohme Llc Novel forms of cyclic dinucleotide compounds
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
EP4412660A1 (en) * 2021-10-04 2024-08-14 Bolt Biotherapeutics, Inc. Asymmetric bis-benzimidazole sting agonist immunoconjugates and uses thereof
US20250108123A1 (en) * 2021-12-17 2025-04-03 Jacobio Pharmaceuticals Co., Ltd. Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
EP4653017A1 (en) * 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
IL322523A (en) * 2023-02-28 2025-10-01 Eisai R&D Man Co Ltd Anti-PSMA antibodies, conjugates and methods of use
CN122180515A (zh) * 2023-06-30 2026-06-09 免疫原公司 包含sting激动剂的组合物和用于治疗神经胶质瘤的使用方法
CN117343111B (zh) * 2023-12-04 2024-02-06 康羽生命科学技术(苏州)有限公司 核苷修饰物n2-异丁酰-2'-甲氧基鸟苷的制备方法
CN120204418A (zh) * 2023-12-27 2025-06-27 上海迪诺医药科技有限公司 环状二核苷酸化合物、其偶联物及应用
WO2026035986A1 (en) 2024-08-07 2026-02-12 Bighat Biosciences, Inc. Humanized anti-cdh17 antibodies and use of the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN108137641B (zh) 2015-08-13 2022-04-01 默沙东公司 作为sting激动剂的环状双核苷酸化合物
GB2552041A (en) * 2015-12-07 2018-01-10 Opi Vi - Ip Holdco Llc Compositions of antibody construct-agonist conjugates and methods thereof
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
DE212016000029U1 (de) 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
WO2018100558A2 (en) * 2016-12-01 2018-06-07 Takeda Pharmaceutical Company Limited Cyclic dinucleotide
RU2019122598A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Циклические динуклеотидные агонисты sting для лечения рака
WO2018118664A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
US11033635B2 (en) 2019-07-19 2021-06-15 Immunesensor Therapeutics, Inc. Antibody-STING agonist conjugates and their use in immunotherapy

Similar Documents

Publication Publication Date Title
JP2025041725A5 (cg-RX-API-DMAC7.html)
JP6328649B2 (ja) 薬物−タンパク質コンジュゲート
JP2024040167A5 (cg-RX-API-DMAC7.html)
JP2020536845A5 (cg-RX-API-DMAC7.html)
KR101988005B1 (ko) 개선된 연결을 갖는 아마톡신-접합체
JPWO2020031936A5 (cg-RX-API-DMAC7.html)
JP2021510696A5 (cg-RX-API-DMAC7.html)
JP2020536847A5 (cg-RX-API-DMAC7.html)
JP2021531826A5 (cg-RX-API-DMAC7.html)
JP4794735B2 (ja) ビタミンb12誘導体及びそれらの製造方法
RU2012157167A (ru) Полифункциональные антительные конъюгаты
JP7256751B2 (ja) β-ガラクトシドが導入された自己犠牲リンカーを含む化合物
JP2010514835A5 (cg-RX-API-DMAC7.html)
IL277049B1 (en) Conjugates of biparatopic anti-HER2 antibody and drug and methods of use
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2025513163A5 (cg-RX-API-DMAC7.html)
JP2023159335A5 (cg-RX-API-DMAC7.html)
JP2020147581A (ja) タンパク薬物複合体で使用するためのリンカーに関連する材料および方法
CN116036303B (zh) 一种抗体-药物偶联物及其制备方法和应用
JP2025026839A5 (cg-RX-API-DMAC7.html)
CN114040778A (zh) 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法
CN108329371B (zh) 白蛋白结合型吉西他滨前药及其合成和应用
JP2015512247A5 (cg-RX-API-DMAC7.html)
CA2338000A1 (en) Water-soluble 4-thio-maleimido derivatives and methods for their production
CN120957755A (zh) 多环类药物偶联物及其制备方法和用途